BioXcel Therapeutics Submits sNDA for At-Home Use of IGALMI® in Agitation Treatment
BTAI sits 58% above its 52-week low of $1.17.
Summary
BioXcel Therapeutics has submitted an sNDA to the FDA for IGALMI® to expand its label for at-home use in treating agitation associated with bipolar disorders or schizophrenia.
Key Events · Product Development and Regulatory · BTAI
-
sNDA Submission for IGALMI®
BioXcel Therapeutics announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for IGALMI® on January 14, 2026.
-
Expanded At-Home Use Indication
The sNDA seeks to expand IGALMI's label to include at-home use for the acute treatment of agitation associated with bipolar disorders or schizophrenia, addressing a market with no currently FDA-approved options.
-
Existing FDA Approval
IGALMI® was previously approved by the FDA in April 2022 for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults under the supervision of a healthcare provider.
Analysis · BTAI · Life Sciences
BioXcel Therapeutics' submission of a supplemental New Drug Application (sNDA) for IGALMI® to include at-home use is a very important development. This expansion targets a significant unmet medical need, as there are currently no FDA-approved options for the acute treatment of agitation associated with bipolar disorders or schizophrenia in an at-home setting. If approved, this could substantially broaden the addressable market for IGALMI®, driving significant revenue growth for the company and potentially transforming its commercial outlook.
At the time of this filing, BTAI was trading at $1.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.2M. The 52-week trading range was $1.17 to $8.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.